CBP-93872
CBP-93872 is a G2 checkpoint inhibitor and a chemosensitizer. CBP-93872 specifically inhibits DNA double-strand break (DSB)-dependent, Nbs1-mediated ATR activation, without directly inhibiting ATR kinase activity or affecting ATR activation induced by other types of DNA damage; meanwhile, it suppresses the pathway between ATM and ATR activation, thereby reducing the autophosphorylation of ATR and the subsequent phosphorylation of Chk1. CBP-93872 does not inhibit DNA end resection at DSB sites. CBP-93872 induces cell death and enhances the cytotoxic effects of platinum-containing compounds and pyrimidine antimetabolites on cancer cells. CBP-93872 can be used in related research on p53-mutant cancers, colorectal cancer, and pancreatic cancer.
For research use only. We do not sell to patients.
- CAS No.: 67427-51-4
- Formula: C10H15BrN2O
- Molecular Weight:259.15
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
Chk1 |
In Vitro
CBP-93872 (20 μM) abrogates the maintenance of IR-induced G2 checkpoint in p53-deficient HT-29, A549 and NCI-H460 cells, but does not affect its initiation; whereas in MCF7 cells with normal p53 function, this compound does not alter the IR-induced G2 checkpoint [1].
CBP-93872 (20 μM) specifically inhibits DSB-induced ATR activation and the downstream ATR-dependent phosphorylation of Chk1, Nbs1, and RPA2 in HT-29 cells, without affecting ATM activation and non-DSB-induced checkpoint signaling pathways[1].
CBP-93872 (>50 μM; 72 h) inhibits the proliferation of colorectal cancer HT29 cells at concentrations above 50 μM after 72 h of treatment[2].
CBP-93872 (>200 μM; 72 h) inhibits the proliferation of Panc-1 pancreatic cancer cells at a concentration higher than 200 μM after 72 h of treatment[2].
CBP-93872 (50 μM; 72 h) enhances Oxaliplatin-induced apoptosis in colorectal cancer HT29 cells, increases the proportion of sub-G1 phase cells to 24.3% after 72 h of combined treatment, and upregulates the expression levels of cleaved caspase 3 and γH2AX[2].
CBP-93872 (50 μM; 48 h) abolishes Oxaliplatin (HY-17371)-induced G2 checkpoint activation in HT29 colorectal cancer cells[2].
CBP-93872 (50 μM; 48 h) abrogates the G2 checkpoint activation induced by Cisplatin (HY-17394) in HT29 colorectal cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT-29 cells
-
Concentration:20 μM
-
Incubation Time:2 h post-IR/UV/MMS treatment; 4 h post-HU treatment; 4, 8 h post-10 Gy IR treatment
-
Result:Strongly compromised IR-induced phosphorylation of Chk1 at serines 317 and 345, as well as ATR autophosphorylation at threonine 1989, but did not affect ATM autophosphorylation at serine 1981 or Chk2 phosphorylation.
Did not alter Chk1 phosphorylation induced by UV, MMS, or HU.
Reduced H3 pS10 levels at 4 hours post-IR, then elevated H3 pS10 levels at 8 hours post-IR.
Inhibited IR-induced phosphorylation of Nbs1 at serine 343 and RPA2 at serine 33, but did not affect UV-induced Nbs1 phosphorylation or the formation of Nbs1-Mre11-Rad50 complexes.
-
Cell Line:HT29 human colorectal cancer cells
-
Concentration:10-200 μM
-
Incubation Time:72 h
-
Result:Suppressed HT29 cell proliferation at concentrations greater than 50 μM after 72 h.
-
Cell Line:Panc-1 human pancreatic cancer cells
-
Concentration:50-500 μM
-
Incubation Time:72 h
-
Result:Suppressed Panc-1 cell proliferation at concentrations greater than 200 μM after 72 h.
-
Cell Line:HT29 human colorectal cancer cells
-
Concentration:50 μM (in combination with 30 μM oxaliplatin)
-
Incubation Time:72 h (flow cytometry); 16, 24, 48, 72 h (immunoblotting)
-
Result:Increased the sub-G1 cell population in HT29 cells from 6.1% to 24.3% after 72 h.
Detected abundant cleaved caspase 3 and elevated γH2AX in cells receiving combined treatment.
Chemical Information
-
CAS No. 67427-51-4
-
Molecular Weight 259.15
-
Formula C10H15BrN2O
-
SMILES
BrC1=CC(=CC=C1NCC(O)CN)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)